COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience
Table 4
Association between mortality and investigations of kidney transplant recipients with COVID-19.
Parameter
Mean (SD)
Mean difference (95% CI)
-value
Survivors (n = 49)
Nonsurvivors (n = 18)
Age (years)
49.18 (13.52)
57.22 (9.56)
8.03 (1.10–14.98)
0.024
Height (meter)
1.666 (0.08)
1.672 (0.08)
0.005 (−0.040 to 0.050)
0.814
Weight (kg)
69.18 (14.4)
73.5 (16.5)
4.32 (−3.93 to 12.56)
0.3
BMI (kg/m2)
20.8 (4.23)
21.7 (4.17)
0.94 (−1.38 to 3.26)
0.42
Transplant duration (weeks)
194 (117–370); n = 49
340 (262–448); n = 18
146 (25.0 to 227.5)
0.016
Haemoglobin (gm %; Hb)
11.46 (2.02)
10.27 (1.97)
−1.19 (−2.29 to −0.085)
0.035
Total leucocyte count (cells/mm3)
8820 (2717)
13211 (5228)
4391 (2437 to 6345)
<0.001
Platelet count (x10 (9)/L)
216.8 (75.18)
167.0 (69.53)
−49.85 (−90.44 to −9.26)
0.017
Serum creatinine (mg/dL)
1.84 (1.18)
2.58 (1.50)
0.74 (0.035 to 1.44)
0.04
Blood urea (mg/dL)
66.61 (32.99)
106.75 (37.42)
40.14 (20.79 to 59.48)
<0.001
Serum albumin (gm/dL)
3.71 (0.56)
3.09 (0.63)
−0.62 (−0.95 to −0.29)
<0.001
Lymphocytes (%)
14.02 (7.59)
8.98 (5.40)
−5.04 (−9.05 to −1.03)
0.015
Presentation SpO2 (%)
95.7 (2.78)
86.94 (5.77)
−8.77 (−10.86 to −6.68)
<0.001
AST (IU/L)
30.63 (11.53)
29.50 (12.15)
−1.13 (−7.81 to 5.56)
0.737
ALT (IU/L)
35.28 (19.60)
29.83 (15.90)
−5.55 (−16.19 to 5.09)
0.301
Inflammatory markers and other important parameters − median (interquartile range) difference (95% CI)
IL-6 (pg/ml)
16.40 (4.10–79.10); n = 29
195.35 (64.7–891.4); n = 14
178.95 (50.3 to 692.2)
<0.001
Procalcitonin (ng/ml)
0.14 (0.05–0.48); n = 29
0.27 (0.11–2.84); n = 15
0.13 (−0.06 to 2.31)
0.101
D-dimer (ng FEU/ml)
590 (300–1350); n = 33
1402 (712–5563); n = 16
812 (27 to 4152)
0.002
CRP (mg/L)
34.45 (9.55–108.22); n = 28
149.6 (59.6–174.3); n = 14
115.11 (10.0 to153.6)
0.002
Ferritin (ng/ml)
522 (205–1438); n = 30
856 (715–1243); n = 16
333.65 (−197.0 to 745.5)
0.115
LDH (IU/L)
317 (257–413); n = 23
417 (291–806); n = 11
100 (−54.0 to 489.0)
0.091
Need of dialysis, n (%)
3 (6.12)
10 (55.6)
53.67 (10.71–269.04)
<0.001$
CT score ≥15&,n (%)
6 (31.6)
9 (82.8)
7.17 (2.04–25.22)
0.008$
Remdesivir
9 (18.4)
14 (77.8)
15.56 (4.13–58.57)
<0.001$
Tocilizumab
1 (2)
6 (33.3)
24.0 (2.63–218.67)
0.005$
Convalescent plasma
7 (14.3)
15 (83.3)
30.0 (6,86–131.19)
<0.001$
Ventilator need
0 (0)
14 (77.8)
—
<0.001#
Acute kidney injury (AKI), n (%)
8 (17.78)
16 (88.9)
37.0 (7.06–194.0)
<0.001$
ICU stay, n (%)
4 (8.2)
15 (83.3)
56.3 (11.3–280.6)
<0.001$
SpO2, oxygen Saturation, Hb, haemoglobin, TLC, total leucocyte count, IL-6, interleukin-6, LDH, lactate dehydrogenase, CRP, C-reactive protein. Average of all available values.&CT score was available for 30, 19 survivor and 11 nonsurvivor. $Odds ratio (95% confidence interval).
